Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0023473 (chronic myeloid leukemia)
 18,916 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In the current study, we have examined the efficacy of a Src/Abl kinase inhibitor SKI-606 (Bosutinib) for its effect on prostate cancer growth and skeletal metastasis. Treatment of highly invasive human prostate cancer cells PC-3 and DU-145 with different doses of SKI-606 decreased Src activation, cell proliferation, migration, and invasion as determined by Matrigel Boyden chamber invasion assay. For in vivo studies, PC-3 cells were inoculated through s.c. or i.t. route into male BALB/c nu/nu or Fox Chase severe combined immunodeficient mice, respectively. Experimental animals treated with SKI-606 developed tumors of a significantly smaller volume and a significant decrease (50%) in experimental skeletal lesion area. A marked increase (32%) in bone volume to tumor volume ratio was also seen by micro-computed tomography analysis of tibias from control and experimental groups of animals. Western blot analysis showed the ability of SKI-606 to significantly decrease the phosphorylation of signaling molecules (AKT, mitogen-activated protein kinase, focal adhesion kinase) and the expression of tumor progression-associated genes uPAR, MMP-2, MMP-9, N-cadherin, fibronectin, BMP-2 (bone morphogenetic protein 2), BMP-6 (bone morphogenetic protein 6), IL-8 (interleukin 8), and TGF-beta (transforming growth factor beta) in prostate cancer cells. SKI-606 is currently in clinical trials for breast cancer and chronic myelogenous leukemia. Results from these studies provide convincing evidence for evaluating its efficacy in prostate cancer patients.
 ...
PMID:SKI-606 (Bosutinib) blocks prostate cancer invasion, growth, and metastasis in vitro and in vivo through regulation of genes involved in cancer growth and skeletal metastasis. 2042 91

To commemorate the 50th anniversary of its discovery, Tuesday, September 28, 2010 was declared "Philadelphia Chromosome Day" by Mayor Michael Nutter of the City of Philadelphia. On that day, the Fox Chase Cancer Center hosted the "Philadelphia Chromosome Symposium: Past, Present and Future" at the Chemical Heritage Foundation, located just a few blocks from the Liberty Bell and Independence Hall. The symposium was conceived by Joseph R. Testa, PhD, who also served as scientific organizer for the event. The symposium included sessions on the discovery and molecular characterization of the abnormality and the development of a successful treatment for chronic granulocytic leukemia. Honored guests included Dr. Peter Nowell, Dr. Janet Rowley, and Mrs. David (Alice) Hungerford.
 ...
PMID:The Philadelphia chromosome: celebration of the 50th anniversary of its discovery. 2143 Mar 53